What drugs are used to treat chronic lymphocytic leukemia (CLL)?

Drugs Used to Treat Chronic Lymphocytic Leukemia (CLL)

The current standard treatment for CLL centers on targeted oral therapies—specifically BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) and the BCL2 inhibitor venetoclax (often combined with obinutuzumab)—which have largely replaced chemoimmunotherapy as first-line therapy for most patients. 1, 2

First-Line Treatment Options

For Patients WITHOUT TP53 Mutation or del(17p)

The choice depends primarily on patient fitness and genetic risk factors:

Preferred Targeted Therapies:

• BTK Inhibitors (continuous therapy until progression):

  • Ibrutinib (with or without rituximab) 1, 2
  • Acalabrutinib (with or without obinutuzumab) 1, 2
  • Zanubrutinib 2

• Time-Limited BCL2 Inhibitor Combinations:

  • Venetoclax + obinutuzumab for 12 cycles 1, 2
  • Ibrutinib followed by ibrutinib-venetoclax (fixed 12 cycles or MRD-guided) 2

Important consideration: Time-limited therapy is increasingly valued when equal evidence exists, as it avoids continuous drug exposure, reduces cost, and prevents resistance development 2.

Chemoimmunotherapy (CIT) - Now Reserved:

CIT should only be considered for patients with mutated IGHV status, no TP53 aberrations, non-complex karyotype, AND when targeted therapies are not reimbursed 2:

• FCR (fludarabine, cyclophosphamide, rituximab): For fit patients <65 years 1, 3
• Bendamustine + rituximab (BR): For fit patients ≥65 years (lower infection risk and secondary malignancy rates than FCR) 1, 3
• Chlorambucil + obinutuzumab: For frail patients with significant comorbidities 1, 3

Critical caveat: FCR carries increased risk of secondary myeloid neoplasms and severe infections, particularly in older patients 1, 3.

For Patients WITH TP53 Mutation or del(17p)

These patients must receive BTK inhibitors as first-line therapy 4, 1:

• Ibrutinib (preferred) 4, 1
• Acalabrutinib 1
• Zanubrutinib 2

Alternative if BTK inhibitors contraindicated:

• Venetoclax + obinutuzumab (though less effective in this subgroup than in TP53-normal patients) 1
• Idelalisib + rituximab (only if no other options available due to severe infectious complications) 4, 1

Chemoimmunotherapy is NOT an option for TP53-aberrant patients due to poor outcomes 1.

Relapsed/Refractory Disease

For Relapse Within 3 Years or Non-Response

Change the therapeutic regimen immediately 1:

Primary options (equal evidence):

• Venetoclax + rituximab for 24 months 1
• Ibrutinib or acalabrutinib (continuous) 1

Alternative options:

• Idelalisib + rituximab 1
• Pirtobrutinib (noncovalent BTKi) for patients previously exposed to covalent BTKis 5, 6

For Relapse After >3 Years

May repeat the initial regimen if it provided durable remission 1.

Sequencing After BCR Inhibitor Failure

If patient fails BTK inhibitor therapy, switch to venetoclax-based therapy (preferred) 4, 1. The reverse sequence (venetoclax failure → BTK inhibitor) is also effective, though less data exist 1.

For double-refractory patients (failed both BTK and BCL2 inhibitors):

• Pirtobrutinib (noncovalent BTKi) 5, 6
• Lisocabtagene maraleucel (CAR T-cell therapy) 5
• Allogeneic stem cell transplantation in fit patients 4, 1

Additional Therapeutic Agents

Monoclonal Antibodies (used in combinations):

• Obinutuzumab (preferred anti-CD20 antibody) 1, 2
• Rituximab 1
• Ofatumumab 3

PI3K Inhibitors (limited use due to toxicity):

• Idelalisib + rituximab (only when BTK inhibitors and venetoclax unsuitable) 4, 1
• Duvelisib 7

Older Chemotherapy Agents (rarely used now):

• Chlorambucil 3
• Bendamustine 3
• Fludarabine 8
• Cyclophosphamide 8
• Cladribine 8

Key Decision-Making Factors

When selecting therapy, evaluate:

1. TP53 status (mutation or del(17p)) - dictates BTK inhibitor use
2. IGHV mutational status - affects CIT consideration
3. Cardiac comorbidities - BTK inhibitors (especially ibrutinib) increase arrhythmia risk 1, 2
4. Renal function - affects venetoclax TLS risk and requires dose ramp-up with close monitoring 1
5. Bleeding risk/anticoagulation - BTK inhibitors increase bleeding 1
6. Patient preference for continuous vs. time-limited therapy 1
7. Drug availability and reimbursement 2

Common pitfall: Do not use ibrutinib in patients with significant cardiac arrhythmias or on anticoagulation without careful consideration—consider acalabrutinib or zanubrutinib as alternatives with better cardiac safety profiles 1, 2.